Trials / Completed
CompletedNCT00396279
Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects With Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine how safe and effective denosumab is in treating patients with giant cell tumor of bone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Denosumab | Administered by subcutaneous injection |
| DIETARY_SUPPLEMENT | Calcium/Vitamin D |
Timeline
- Start date
- 2006-07-10
- Primary completion
- 2008-04-07
- Completion
- 2011-02-01
- First posted
- 2006-11-06
- Last updated
- 2022-11-08
- Results posted
- 2014-03-05
Source: ClinicalTrials.gov record NCT00396279. Inclusion in this directory is not an endorsement.